Cash Flow

v3.22.2.2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash flows from operating activities    
Net (loss) income from continuing operations $ (2,745,520) $ 511,711
(Loss) income from discontinued operations (45,511) 1,147,472
Net loss from operations (2,700,009) (635,761)
Adjustments to reconcile net (loss) income from continuing operations to net cash (used) provided by operating activities:    
Depreciation and amortization 1,075,393 156,340
Amortization of loan costs 49,158 0
Change in deferred tax asset (729,483) 0
Shares issued for services 0 175,000
Shares issued for finders fee 0 33,740
Change in derivative liability 1,770 0
Stock based compensation 927,326 593,098
Changes in assets and liabilities, net of acquired amounts    
Accounts receivable (139,539) 19,689
Inventory (912,492) (420,808)
Prepaid expenses and other assets (716,263) 210,695
Accounts payable and accrued liabilities 1,050,492 279,895
Accrued liabilities related to acquisition (139,233) (482,235)
Deferred revenue 15,125 0
Net cash used by operating activities - Continuing Operations (2,217,755) (70,347)
Net cash (used) provided by operating activities - Discontinued Operations (292,177) 887,704
Net cash (used) provided by operating activities (2,509,932) 817,357
Cash flows from investing activities    
Acquisition of Lucky Tail (2,000,000) 0
Acquisition of VitaMedica, Inc., net of cash acquired (500,000) (2,000,000)
Acquisition of property and equipment (148,208) (166,869)
Net cash used in investing activities - Continuing Operations (2,648,208) (2,166,869)
Net cash used in investing activities - Discontinued Operations 0 0
Net cash used in investing activities (2,648,208) (2,166,869)
Cash flows from financing activities    
Payment of note payable (163,003) (150,000)
Proceeds from issuance of related party notes payable 1,470,000 0
Net cash provided (used) by financing activities - Continuing Operations 1,306,997 (150,000)
Net cash provided by financing activities - Discontinued Operations 0 0
Net cash provided (used) by financing activities 1,306,997 (150,000)
Net decrease in cash - Continuing Operations (3,558,966) (2,387,216)
Net (decrease) increase in cash - Discontinued Operations (292,177) 887,704
Cash, beginning of period 7,149,806 14,534,211
Cash, end of period 3,298,663 13,034,699
Supplemental cash flow disclosures    
Interest paid 239,117 0
Income tax paid 0 0
Issuance of common stock for acquisition of Infusionz 0 1,764,876
Issuance of common stock for acquisition of VitaMedica 0 482,000
Issuance of debt for the acquisition of VitaMedica 0 1,000,000
Liabilities assumed from acquisition of VitaMedica 0 (309,574)
Liabilities assumed from acquisition of LuckyTail 1,490,822 0
Stock issued for construction services for property and equipment $ 70,350 $ 0

Source